Тиберал (Ornidazole) is a therapeutic agent used for the management of specific infectious diseases. It is utilized to address illnesses caused by certain protozoa and anaerobic bacteria, where targeted antimicrobial action is necessary to help facilitate symptomatic improvement.

Clinical use includes addressing amoebiasis (infections of the liver and intestines), giardiasis (lambliasis), and trichomoniasis (a common protozoal infection). It is also indicated for managing infections caused by anaerobic bacteria in various clinical settings. Furthermore, this medication may be used as a prophylactic measure before specific surgical procedures where the risk of postoperative anaerobic infection is a consideration.

Quick Fact: Relief for Intestinal Distress (associated with susceptible parasitic infections)

Eligibility Profile: Official Regulatory Information

Тиберал (Ornidazole) use is strictly defined by regulatory eligibility criteria that classify patients into approved, restricted, and contraindicated groups. All eligibility rules are derived from official government-approved prescribing information.

Populations for Whom Use is Prohibited (Contraindicated)

Condition	Status
Hypersensitivity	Prohibited (Contraindicated) to ornidazole or other nitroimidazole drugs.
Pregnancy	Prohibited (Contraindicated) during the first trimester.
Neurological Conditions	Prohibited in certain organic central nervous system (CNS) diseases, including epilepsy.

Restricted and Conditional Use

Use is established for adults and children, but limitations apply. The use in children is restricted by a requirement for specific weight-based dosing.

Patients with severe hepatic impairment (e.g., liver cirrhosis) require conditional use, necessitating a doubled dosing interval due to the drug's altered elimination profile. Patients undergoing haemodialysis require a supplemental dose. Beyond the first trimester, use during pregnancy is conditional and only permitted when medically absolutely necessary.

Use in nursing mothers is generally not recommended unless necessary, and may require the interruption of breastfeeding.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Тиберал (Ornidazole) through specific pharmacokinetic and pharmacodynamic constraints. These constraints primarily involve agents that alter the drug's plasma concentration or those with additive systemic effects.

Documented Interaction Outcomes

Interacting Substance	Official Regulatory Outcome
Coumarin-type oral anticoagulants (e.g., Warfarin)	Potentiation of the anticoagulant effect is documented, requiring increased monitoring of the International Normalized Ratio (INR).
Non-depolarizing muscle relaxants (e.g., Vecuronium)	Prolongation of the muscle relaxant effect is officially noted.
Lithium	Ornidazole may increase the plasma concentration of Lithium, warranting closer monitoring of serum levels.
Cimetidine	Decreases the plasma clearance and prolongs the half-life of Ornidazole.
Phenobarbital / Phenytoin	May reduce the half-life of Ornidazole.
5-Fluorouracil (5-FU)	Ornidazole is documented to reduce the clearance of 5-FU.

Administration Restrictions

Ingestion of alcohol (ethanol) is prohibited during treatment and for a mandatory separation period of at least 3 days after discontinuation of Ornidazole. Furthermore, co-administration is formally restricted in individuals with chronic alcoholism. In cases of severe hepatic impairment, the drug's elimination half-life is longer and clearance is reduced, which necessitates a formal adjustment to the administration interval to prevent drug accumulation.

The drug's action begins with its status as a prodrug, requiring a unique biochemical environment for activation. This transformation is initiated by microbial nitroreductase enzymes, such as ferredoxins, found specifically in anaerobic bacteria and protozoa. This selective, enzyme-dependent process ensures that the active, cytotoxic form of the drug is primarily generated within the infectious microbe, a mechanism that maintains selective toxicity toward the pathogen due to the enzyme concentration difference in human host cells.

Upon activation, the drug is converted into highly reactive free nitro radicals. These chemical intermediates act as the primary molecular weapon by rapidly and covalently binding to the pathogen's DNA. This interaction causes strand breakage and structural damage to the microbe's genome. This chemical action results in the destruction of the genetic blueprint, initiating an irreversible cytotoxic cascade. The resulting genomic damage immediately and comprehensively inhibits key cellular pathways, particularly nucleic acid and protein synthesis. The cessation of this fundamental biosynthetic machinery prevents the pathogen's ability to maintain cell integrity and replicate. This final functional consequence results in protozoacidal and bactericidal activity against susceptible organisms.

Тиберал (Ornidazole) is administered via two primary routes: the 500 mg film-coated tablet for oral consumption, or a solution for intravenous infusion for systemic delivery. Dosing regimens are fixed and dependent on the specific infection being treated and the duration of therapy.

Administration Guidelines

The core administration schedule requires either a single dose of up to 2000 mg for acute or one-day courses, or a twice-daily divided dose of 500 mg in the morning and evening for multi-day treatments. For maintenance therapy via infusion, 500 mg is typically administered every 12 hours following an initial loading dose. Treatment is generally short-term, with duration patterns spanning from 1 to 10 days, or 3 to 5 days when used for postoperative prophylaxis.

Procedural Requirements and Adjustments

To ensure proper use, the oral tablets must be taken after meals and must be swallowed whole with water. The solution for infusion requires prior dilution to a concentration of 5 mg/mL or less and is administered slowly over 15 to 30 minutes. Specific adjustments are utilized for different patient populations: the dosing interval is doubled for patients diagnosed with severe hepatic impairment, and pediatric dosing is calculated using a weight-based standard of 25 mg/kg to 40 mg/kg per day. This structured approach outlines how the medication is handled and taken.

Research evidence / Overview of studies for Тиберал (Ornidazole)

Evidence for Use in Protozoal Infections (Amoebiasis and Giardiasis)

The research into Ornidazole's application in protozoal infections like amoebiasis and giardiasis primarily includes short-term Randomized Controlled Trials (RCTs) and systematic reviews. These studies have been used in research exploring how symptoms change over time and have focused on how the medication performed in studies examining parasite clearance. Studies reported measurements of clearance rates that were observed in these populations, with reported outcomes being short-term. However, follow-up durations were limited in many studies, meaning that long-term effects are not fully established regarding the patterns of recurrence observed over many months or years.

Evidence for Use in Managing Anaerobic Bacterial Infections

Research has examined Ornidazole in studies involving susceptible anaerobic bacteria, such as those found in intra-abdominal and oral infections. Research includes RCTs and extensive in vitro laboratory testing. Studies monitored outcomes related to systemic or functional imbalance, such as the resolution of fever and inflammation. Clinical trials reported measurements of clinical improvement and microbiological clearance rates that were reported in studies that also included other anti-anaerobic agents as comparators. The evidence quality varies across studies due to the high heterogeneity of infection sites and severity levels examined.

Evidence for Use in Surgical Prophylaxis

Research has examined Ornidazole's role as a prophylactic (preventive) measure used before high-risk surgical procedures to reduce the chance of post-operative anaerobic infection. Findings indicate that studies reported measurements of infection rates in groups that received the prophylactic regimen in specific surgical contexts, with control groups often included for comparison. Limited information is available on the development of antimicrobial resistance patterns in the long term following this preventive use.

What Is Still Uncertain About Тиберал Research

While Ornidazole was studied for several indications, certainty remains low in certain areas. Comparative evidence is lacking for many direct, modern comparisons against newer anti-anaerobic agents. The results apply only to the populations studied, and there is a recognized gap in understanding the long-term patterns of recurrence of parasitic diseases.

Key Studies & References

1. Saudi Public Assessment Report (Ornivoda) - Review of clinical studies on Ornidazole (includes specific RCTs comparison to Metronidazole, Tinidazole, and Clindamycin)
2. Efficacy of ornidazole for pericoronitis: a meta-analysis and systematic review (reflecting use in anaerobic dental/oral infections)
3. Bioavailability File : Ornidazole (includes pharmacokinetics relevant to dosing frequency/half-life and tissue penetration for prophylaxis)
4. NICE Guideline NG125: Surgical site infections: prevention and treatment (used for context on surgical prophylaxis best practice)

Common questions about Тиберал (FAQ)

Q: Is Тиберал an antibiotic?

Official documents classify this medicine as an antimicrobial and antiprotozoal agent. This means it is used to target certain harmful microorganisms like anaerobic bacteria and protozoa. It belongs to a chemical group known as nitroimidazole derivatives.

Q: What is the safety classification of Тиберал?

The medicine is a prescription-only (Rx) drug, meaning a healthcare provider must prescribe it. Official regulatory guidelines prohibit its use in the first three months of pregnancy and in certain Central Nervous System (CNS) diseases.

Q: Are there any long-term side effects associated with Тиберал?

Official documents list potential severe reactions, including a nerve condition called peripheral neuropathy, which may be long-lasting. Research summaries have also noted that long-term follow-up is not fully established, particularly regarding patterns of disease recurrence.

Q: What kind of food or drinks should I avoid while on Тиберал?

Official regulatory text strictly prohibits the ingestion of alcohol (ethanol) during treatment. This prohibition continues for a mandatory period of at least 3 days after you finish taking the medicine. The labeling does not explicitly mention prohibitions for other foods or non-alcoholic drinks.

Q: Can people with kidney problems use Тиберал?

Official regulatory documents address the use of this medicine in patients with kidney function issues. For example, guidelines specify that patients undergoing haemodialysis require a supplemental dose. Regulatory labeling does not specifically detail use or dose adjustment for non-dialysis-dependent kidney impairment.

Q: What is the typical age range for people prescribed Тиберал?

Use of the medicine is established for both adults and children. Dosing for children is specifically calculated using a weight-based standard per kilogram to ensure appropriate administration.

Q: Are there studies comparing Тиберал to placebo?

Research overviews mention that clinical trials investigating the medicine’s use often include control groups for comparison. The inclusion of control groups in clinical trials is generally intended for comparison, which may involve using a placebo or an active substance.

Q: Why is it important to avoid alcohol while taking Тиберал?

Regulatory documents enforce a strict prohibition on alcohol intake. This restriction is necessary because the medicine belongs to a drug class known for causing a severe adverse reaction (Disulfiram-like) if combined with alcohol.

Q: What are the official guidelines about taking Тиберал if I have a history of blood disorders?

Official regulatory documents advise checking leukocyte (white blood cell) counts before and after the start of therapy, particularly for prolonged treatment courses. This monitoring relates to the drug’s potential effects on blood composition.

Q: Does the official information list any severe skin reactions with Тиберал?

Official documents list pruritus (itching) as a Rare side effect and anaphylaxis as a potential serious adverse reaction. Anaphylaxis is a potential serious adverse reaction that is listed in official documents.

Q: Can Тиберал be used to treat bacterial vaginosis?

Official labeling indicates the medicine is used for infections caused by susceptible anaerobic bacteria and protozoa. The medicine’s classification as an agent against anaerobic bacteria relates to the types of organisms that cause this condition.

Q: Does Тиберал help with H. pylori?

Official treatment guidelines often recommend a drug from the nitroimidazole derivative class—which includes Ornidazole—as part of a multi-drug regimen. This combination is used in the treatment regimen for H. pylori infection in the stomach.

Q: Is a metallic taste in the mouth normal when using Тиберал?

Official regulatory text lists a general impairment of taste as a Rare side effect of the medicine. This general term can include reports of a metallic or unpleasant taste in the mouth.

Q: Is it necessary to finish the entire course of Тиберал even if I feel better?

The administration schedule defines a fixed treatment duration. The general principle of using antimicrobial medicines is to complete the entire prescribed course to ensure the infection is fully addressed and to prevent the development of drug resistance.

Q: Is Тиберал generally prescribed to older adults?

Official labeling implies use in the general adult population unless a specific restriction is noted. Dosing adjustments are only specifically mandated for certain conditions, such as severe hepatic impairment (liver function problems).

Q: What does the research evidence say about the effectiveness of Тиберал for trichomoniasis?

Regulatory information and related sources confirm that the drug has established dosage regimens defined for the treatment of trichomoniasis. This confirms the medicine has established dosage regimens defined for this specific protozoal infection.

Q: Is it normal to have dark urine while on Тиберал?

Dark urine is a symptom sometimes observed with drugs in this class, and it is listed as something to monitor. Additionally, other medicines in the same nitroimidazole class are documented to cause non-harmful urine discoloration.

Q: What precautions are advised for driving or operating machinery while on Тиберал?

Official documents list nervous system side effects such as dizziness, somnolence (drowsiness), and vertigo (spinning sensation). Due to these potential reactions, the labeling often includes precautions related to performing tasks like driving or operating machinery.

Storage and Disposal Conditions for Тиберал (Ornidazole)

Official Storage Requirements

To maintain product integrity, the drug must be stored at a temperature not exceeding 30 ,mathrmC in a cool, dry place. It is mandatory to keep the film-coated tablets in their original blister pack until the time of administration to ensure protection from moisture and light. The medicine must always be stored out of the sight and reach of children, as required by the regulatory labeling.

Storage Rule	Requirement
Maximum Temperature	Store below 30 ,mathrmC
Container Rule	Must remain in original blister pack
Child Safety	Keep out of reach of children

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements for pharmaceutical waste. Individuals should consult a pharmacist for guidance on the proper method for discarding unused tablets, ensuring adherence to environmental regulations.